title: Antiangiogenesis research is booming, as questions and studies proliferate.
authors.forename: Vicki
authors.initials: V
authors.lastname: Brower
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000068258:Bevacizumab; D014408:Biomarkers, Tumor / Q000032:analysis; D015179:Colorectal Neoplasms / Q000098:blood supply / Q000188:drug therapy* / Q000401:mortality*; D004334:Drug Administration Schedule; D006801:Humans; D020286:Pericytes / Q000187:drug effects; D016032:Randomized Controlled Trials as Topic; D016019:Survival Analysis
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D014408:Biomarkers, Tumor; D000068258:Bevacizumab